A single-arm, multi-center phase II trial of bendamustine/rituximab induction followed by venetoclax and rituximab consolidation for the frontline treatment of chronic lymphocytic leukemia

Protocol: 
AAAR6357
Phase: 
II

A single-arm, multi-center phase II trial of bendamustine/rituximab induction followed by venetoclax and rituximab consolidation for the frontline treatment of chronic lymphocytic leukemia

The purpose of this study is to determine the effectiveness of the study
treatment- bendamustine and rituximab (BR) followed by venetoclax for 12
months. The combination of the drugs bendamustine and rituximab is a commonly
used treatment for your disease. Venetoclax is an oral drug that blocks a
protein called BCL-2 which is present on CLL cells. With this combination we
hope to increase response to therapy and reduce the risk of tumor lysis
syndrome. In addition, we hope to reduce the total time on therapy by limiting
treatment with venetoclax to 12 months in duration.

Are you Eligible? (Inclusion Criteria)

To be eligible for this study, patients must:
- Be at least 18 years of age with a diagnosis of CLL or SLL
- Be able to do work independently
- Have adequate organ function

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States